Saltar ao contido principal
Páxinas persoais  »  María Isabel Loza García

 

 

Mabel Loza García

Coordinadora del Grupo Biofarma

Catedrática

 

 

Contacto

Email: mabel.loza@usc.es

Teléfono: 881 815460

Web Biofarma: http://www.usc.es/biofarma/

 

 

Publicaciones

 

2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 - 1997 - 1996 - 1995 - 1994 - 1993 - 1992 - 1991 - 1988

 

Año 2017


 

Iglesias A, Cimadevila M, Isabel Cadavid M, Isabel Loza M, Brea J.
Serotonin-2A homodimers are needed for signalling via both phospholipase A2 and phospholipase C in transfected CHO cells.
2017 Feb 16. pii: S0014-2999(17)30095-X. doi: 10.1016/j.ejphar.2017.02.028

 

Carbajales C, Azuaje J, Oliveira A, Loza MI, Brea JM, Cadavid MI, Masaguer CF, García-Mera X, Gutiérrez-de-Terán H, Sotelo E.
Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates.
J Med Chem. 2017 Apr 3. doi: 10.1021/acs.jmedchem.7b00138. [Epub ahead of print]

 

García AM, Salado IG, Perez DI, Brea J, Morales-García JA, González-García A, Cadavid MI, Loza MI, Luque FJ, Perez-Castillo A, Martinez A, Gil C.
Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.
2017 May 9. doi: 10.4155/fmc-2017-0005.

 

Rodríguez-Vázquez N, García-Fandiño R, Aldegunde MJ, Brea J, Loza MI, Amorín M, Granja JR.
cis-Platinum Complex Encapsulated in Self-Assembling Cyclic Peptide Dimers.
2017 May 9. doi: 10.4155/fmc-2017-0005.

 

Azuaje J, Jespers W, Yaziji V, Mallo A, Majellaro M, Caamaño O, Loza MI, Cadavid MI, Brea J, Åqvist J, Sotelo E, Gutiérrez-de-Terán H.
Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists.
2017 Aug 21. doi: 10.1021/acs.jmedchem.7b00860.

 

García AM, Brea J, González-García A, Pérez C, Cadavid MI, Loza MI, Martinez A, Gil C.
Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects.
Molecules. 2017 Sep 4;22(9). doi: 10.3390/molecules22091472.

 

Azuaje J, López P, Iglesias A, de la Fuente RA, Pérez-Rubio JM, García D, Stepniewski TM, García-Mera X, Brea JM, Selent J, Pérez D, Castro M, Loza MI, Sotelo E.
Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors.
Sci Rep. 2017 Sep 7;7(1):10765. doi: 10.1038/s41598-017-11370-2.

 

Iglesias A, Cimadevila M, la Fuente RA, Martí-Solano M, Cadavid MI, Castro M, Selent J, Loza MI, Brea J.
Serotonin 2A receptor disulfide bridge integrity is crucial for ligand binding to different signalling states but not for its homodimerization.
Eur J Pharmacol. 2017 Sep 9. pii: S0014-2999(17)30594-0. doi: 10.1016/j.ejphar.2017.09.011.

 

 

Año 2016


 

Iria Salvadó, Ilaria Gamba, Javier Montenegro, José Martínez-Costas, Jose Manuel Brea, María Isabel Loza, Miguel Vázquez López and M. Eugenio Vázquez.
Membrane-disrupting iridium(III) oligocationic organometallopeptides.
2016 Sept 21;52(73): 11008-11011. doi: 10.1039/C6CC05537K.

 

Daniela Digles, Barbara Zdrazil, Jean-Marc Neefs, Herman Van Vlijmen, Christian Herhaus, Andrei Caracoti, José Brea, Begoña Roibás, María Isabel Loza, Núria Queralt Rosinach, Laura I. Furlong, Anna Gaulton, Luca Bartek, S Senger, Christine Chichester, Ola Engkvist, Chris T. Evelo, Natalie Irene Franklin, Derek Marren, Gerhard F. Ecker and Edgar Jacoby.
Open PHACTS Computational Protocols for in silico Target Validation of Cellular Phenotypic Screens: Knowing the Knowns.
Med. Chem. Commun. First published online 11 May 2016. Indice de impacto: 2.495 (JCR 2014).Q

 

Iglesias A, Lage S, Cadavid MI, Loza MI, Brea J.
Development of a Multiplex Assay for Studying Functional Selectivity of Human Serotonin 5-HT2A Receptors and Identification of Active Compounds by High-Throughput Screening.
J Biomol Screen. 2016 Apr 19. Indice de impacto: 2.423 (JCR 2014). Q2.

 

Tello JS, Myers JA, Macía MJ, Fuentes AF, Cayola L, Arellano G, Loza MI, Torrez V, Cornejo M, Miranda TB, Jørgensen PM.
Elevational gradients in ß-diversity reflect variation in the strength of local community assembly mechanisms across spatial scales
PLOS One. 2015 Mar 24;10(3).doi: 10.1371/journal.pone.0121458.

 

Kaczor AA, Silva AG, Loza MI, Kolb P, Castro M, Poso A.
Structure-Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics.
ChemMedChem. 2016 Apr 5;11(7):718-29. Indice de impacto: 2.968 (JCR 2014). Q2.

 

Gamba I, Salvadó I, Brissos RF, Gamez P, Brea J, Loza MI, Vazquez ME, López MV.
High-affinity sequence-selective DNA binding by iridium(III) polypyridyl organometallopeptides.
Chem Commun. 2016 Jan 7; 52 (6): 1234-7.

 

Castillo J, Loza MI, Mirelman D, Brea J, Blanco M, Sobrino T, Campos F.
A novel mechanism of neuroprotection: Blood glutamate grabber.
J Cereb Blood Flow Metab. 2016 Feb;36(2):292-301.

 

Anton-Torrecillas C, Loza MI, Brea J, Gonzalez-Gomez JC.
Concise asymmetric syntheses of novel phenanthroquinolizidines.
Org Biomol Chem. 2016 Jan 21.

 

 

inicio

Año 2015


 

Kucwaj-Brysz K, Warszycki D, Podlewska S, Witek J, Witek K, González Izquierdo A, Satała G, Loza MI, Lubelska A, Latacz G, Bojarski AJ, Castro M, Kieć-Kononowicz K, Handzlik J.
Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation.
Eur J Med Chem. 2016 Apr 13;112:258-69. Indice de impacto: 3.447 (JCR 2014). Q1.

 

Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Alemán Resto Y, Alsibaee A, Alzualde A, Andrews KT, Avery SV, Avery VM, Ayong L, Baker M, Baker S, Ben Mamoun C, Bhatia S, Bickle Q, Bounaadja L, Bowling T, Bosch J, Boucher LE, Boyom FF, Brea J, Brennan M, Burton A, Caffrey CR, Camarda G, Carrasquilla M, Carter D, Belen Cassera M, Chih-Chien Cheng K, Chindaudomsate W, Chubb A, Colon BL, Colón-López DD, Corbett Y,Crowther GJ, Cowan N, D'Alessandro S, Le Dang N, Delves M, DeRisi JL, Du AY, Duffy S, Abd El-Salam El-Sayed S, Ferdig MT, Fernández Robledo JA, Fidock DA, Florent I, Fokou PV, Galstian A, Gamo FJ, Gokool S, Gold B, Golub T, Goldgof GM, Guha R, Guiguemde WA, Gural N, Guy RK, Hansen MA, Hanson KK, Hemphill A, Hooft van Huijsduijnen R, Horii T, Horrocks P, Hughes TB, Huston C, Igarashi I, Ingram-Sieber K, Itoe MA, Jadhav A, Naranuntarat Jensen A, Jensen LT, Jiang RH, Kaiser A, Keiser J, Ketas T, Kicka S, Kim S, Kirk K, Kumar VP, Kyle DE, Lafuente MJ, Landfear S, Lee N, Lee S, Lehane AM, Li F, Little D, Liu L, Llinás M, Loza MI, Lubar A, Lucantoni L, Lucet I, Maes L, Mancama D, Mansour NR, March S, McGowan S, Medina Vera I, Meister S, Mercer L, Mestres J, Mfopa AN, Misra RN, Moon S, Moore JP, Morais Rodrigues da Costa F, Müller J, Muriana A, Nakazawa Hewitt S, Nare B, Nathan C, Narraidoo N, Nawaratna S, Ojo KK, Ortiz D, Panic G, Papadatos G, Parapini S, Patra K, Pham N, Prats S, Plouffe DM, Poulsen SA, Pradhan A, Quevedo C, Quinn RJ, Rice CA, Abdo Rizk M, Ruecker A, St Onge R, Salgado Ferreira R, Samra J, Robinett NG, Schlecht U, Schmitt M, Silva Villela F, Silvestrini F, Sinden R, Smith DA, Soldati T, Spitzmüller A, Stamm SM, Sullivan DJ, Sullivan W, Suresh S, Suzuki BM, Suzuki Y, Swamidass SJ, Taramelli D, Tchokouaha LR, Theron A, Thomas D, Tonissen KF, Townson S, Tripathi AK, Trofimov V, Udenze KO, Ullah I, Vallieres C, Vigil E, Vinetz JM, Voong Vinh P, Vu H, Watanabe NA, Weatherby K, White PM, Wilks AF, Winzeler EA, Wojcik E, Wree M, Wu W, Yokoyama N, Zollo PH, Abla N, Blasco B, Burrows J, Laleu B, Leroy D, Spangenberg T, Wells T, Willis PA.
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
Eur J Med Chem. 2016 Apr 13;112:258-69. Indice de impacto: 3.447 (JCR 2014). Q1.

 

Anton-Torrecillas C, Bosque I, Gonzalez-Gomez JC, Loza MI, Brea J.
Syntheses and cytotoxicity of (R)- and (s)-7-methoxycryptopleurine.
J org Chem. 2015 Jan 16;80(2):1284-90.

 

Sabatini S, Manfroni G, Barreca ML, Bauer SM, Gargaro M, Cannalire R, Astolfi A, Brea J, Vacca C, Pirro M, Massari S, Tabarrini O, Loza MI, Fallarino F, Laufer SA, Cecchetti V.
The pyrazolobenzothiazine core as a new chemotype of p38 alpha mitogen-activated protein kinase inhibitors.
Chem Biol Drug Des. 2015 Jan 14.

 

Varela MJ, Lage S, Caruncho HJ, Cadavid MI, Loza MI, Brea J.
Reelin influences the expression and function of dopamine D2 and serotonin 5-HT2A receptors: A comparative study.
PNeuroscience 2015. Apr 2;290:165-174.

 

Marti-Solano M, Iglesias A, de Fabritiis G, Sanz F, Brea J, Loza MI, Pastor M, Selent J.
Detection of New Biased Agonists for the Serotonin 5-HT2A Receptor: Modeling and Experimental Validation.
Chem Biol Drug Des. 2015 Jan 14.

 

Pau A, Catto M, Pinna G, Frau S, Murineddu G, Asproni B, Curzu MM, Pisani L, Leonetti F, Loza MI, Brea J, Pinna GA, Carotti A.
Multitarget-Directed Tricyclic Pyridazinones as G Protein-Coupled Receptor Ligands and Cholinesterase Inhibitors.
ChemMedChem. 2015;10(6):1054-70.

 

Ferreira da Costa J, García-Mera X, Caamaño O, Brea JM, Loza MI.
Synthesis by microwave-assisted 1,3-dipolar cycloaddition of 1,2,3-triazole 1'-homo-3'-isoazanucleosides and evaluation of their anticancer activity.
Eur J Med Chem. 2015;98:212-220.

 

Rodriguez A, Guerrero A, Gutierrez de Terán H, Rodriguez D, Brea J, Loza MI, Rosell G, Bosh MP.
New selective A2A agonists and A3 antagonists for human adenosine receptors: synthesis, biological activity and molecular docking studies.
MedChemComm, 2015. Advance Article.

 

Tello JS, Myers JA, Macía MJ, Fuentes AF, Cayola L, Arellano G, Loza MI, Torrez V, Cornejo M, Miranda TB, Jørgensen PM.
Elevational gradients in β-diversity reflect variation in the strength of local community assembly mechanisms across spatial scales.
PLOS One. 2015 Mar 24;10(3).

 

 

inicio

Año 2014


 

Ratnam J, Zdrazil B, Digles D, Cuadrado-Rodriguez E, Neefs JM, Tipney H, Siebes R, Waagmeester A, Bradley G, Chau CH, Richter L, Brea J, Evelo CT, Jacoby E, Senger S, Loza MI, Ecker GF, Chichester C.
The Application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to Support Drug Discovery Research.
PLoS One. 2014 Dec 18;9(12). 1-32.

 

García AM, Brea J, Morales-García JA, Perez DI, González A, Alonso-Gil S, Gracia-Rubio I, Ros-Simó C, Conde S, Cadavid MI, Loza MI, Perez-Castillo A, Valverde O, Martinez A, Gil C.
Modulation of cAMP – Specific PDE without Emetogenic Activity: New Sulfide-Like PDE7 Inhibitors.
J Med Chem 2014 Oct 23; 57 (20):8590-607. Indice de Impacto: 5.480 (JCR 2013).

 

Rodríguez D, Brea J, Loza MI, Carlsson J.
Structure-based discovery of selective serotonin 5-HT1B receptor ligands.
Structure. 2014 Aug 5;22(8):1140-51.

 

Bosque I, Gonzalez-Gomez JC, Loza MI, Brea J.
Natural Tetraponerines: A General Synthesis and Antiproliferative Activity.
J Org Chem. 2014 May 2; 79(9): 3982-91.

 

Selent J, Marti-Solano M, Rodríguez J, Atanes P, Brea J, Castro M, Sanz F, Loza MI, Pastor M.
Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles.
Eur J Med Chem. 2014. Apr 22;77:91-5.

 

Carro L, Torrado M, Raviña E, Masaguer CF, Lage S, Brea J, Loza MI.
Synthesis and biological evaluation of a series of aminoalkyl-tetralones and tetralols asdual dopamine/serotonin ligands.
Eur J Med Chem. 2014;71:237-49.

 

 

inicio

Año 2013


 

Insua I, Alvarado M, Masaguer CF, Iglesias A, Brea J, Loza MI, Carro L.
Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D3 receptor ligands.
Bioorg Med Chem Lett. 2013 Oct 15; 23(20):5586-91.Indice de impacto: 2.338 (JCR 2012).

 

Redondo M, Soteras I, Brea J, González-García A, Cadavid MI, Loza MI, Martínez A, Gil C, Campillo N.
Unraveling phosphodiesterase surfaces. Identification ofphosphodiesterase 7 allosteric modulation cavities.
Eur J Med Chem. 2013 Nov.(70):782-788. Indice de impacto: 3.499 (JCR 2012).

 

Crespo A, El Maatougui A, Biagini P, Azuaje J, Coelho A, Brea J, Loza MI, Cadavid MI, Garcia-Mera X, Gutierrez de Terán H, Sotelo E.
Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Pontent and Selective A(2B) Adenosine Receptor Antagonists.
ASC Med Chem Lett. 2013;4(11): 1031-1036. DOI:10.1021/ml400185v.

 

Atanes P, Lacivita, Rodriguez J, Brea J, Burgueño J, Vela JM, Cadavid MI, Loza MI, Leopoldo M, Castro M.
The arylpiperazine derivatives N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT7 receptor binding and cAMP signaling.
Pharmacology Research and Perspectives. Article firt published online: 5 dec 2013.

 

Yaziji V, Rodriguez D, Coelho A, García-Mera X, El Maatougui A, Brea J, Loza MI, Gutiérrez-de-Terán H, Sotelo E.
Selective and potent adenosine A (3) receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl) acetamide scaffold.
Eur J Med Chem. 2013 Jan; 59C: 235-242. Indice de impacto: 3.346 (JCR 2011).

 

De las Casas-Engel M, Domínguez-Soto A, Sierra-Filardi E, Bragado R, Nieto C, Puig-Kroger A, Samaniego R, Loza M, Corcuera MT, Gómez-Aguado F, Bustos M, Sánchez-Mateos P, Corbí AL.
Serotonin Skews Human Macrophage Polarization through HTR2B and HTR7.
J Immunol.2013 Jan 25;190(5):2301-10. Indice de impacto: 5.788 (JCR 2011).

 

Cambón A, Rey-Rico A, Mistry D, Brea J, Loza MI, Attwood D, Barbosa S, Alvarez-Lorenzo C, Concheiro A, Taboada P, Mosquera V.
Doxorubicin-loaded micelles of reverse poly(butylene oxide)-poly(ethylene oxide)-poly(butylene oxide) block copolymers as efficient "active" chemotherapeutic agents.
Int J Pharm. 2013 Feb 1; 445(1-2):47-57. Indice de impacto: 3.350 (JCR 2011).

 

Cambón A, Rey-Rico A, Barbosa S, Soltero JF, Yeates SG, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, Taboada P, Mosquera V.
Poly(styrene oxide)-poly(ethylene oxide) block copolymers: From "classical" chemotherapeutic nanocarriers to active cell-response inducers.
J Control Release. 2013; 167(1):68-75. Indice de impacto: 6.499 (JCR 2011).

 

Azzaoui K, Jacoby E, Senger S, Rodríguez EC, Loza M, Zdrazil B, Pinto M, Williams AJ, de la Torre V, Mestres J, Pastor M, Taboureau O, Rarey M, Chichester C, Petiffer S, Blomberg N, Harland L, Williams-Jones B, Ecker GF.
Scientific competency questions as the basis for semantically enriched open pharmacological space development.
Drug Discov Today. 2013 Sept; 18(17-18):843-52. Indice de impacto: 6.838 (JCR 2011).

 

Cambon A, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, Barbosa S, Taboada P, Mosquera V.
Cytocompatibility and P-glycoprotein inhibition of block copolymers: structure-activity relationship.
Mol Pharm. 2013 Aug 5; 10(8): 3232-41. Imdice de impacto: 4,782 (JCR 2011).

 

 

inicio

Año 2012


 

Oyarzun-Ampuero FA, Brea J, Loza MI, Alonso MJ, Torres D.
A Potential Nanomedicine Consisting of Heparin-Loaded Polysaccharide Nanocarriers for the Treatment of Asthma.
Macromol Biosci. 2012; 12(2):176-83. Indice de impacto: 3.886 (JCR 1011).

 

Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C.
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Eur J Med Chem 2012; 47(1):175-85. Indice de impacto: 3,346 (JCR 2011).

 

Redondo M, Brea JM, Perez DI, Soteras I, Val C, Pérez C, Morales-Garcia JA, Alonso-Gil S, Paul-Fernandez N, Martin-Alvarez R, Cadavid I, Loza I, Perez-Castillo A, Mengod G, Campillo NE, Martinez A, Gil C.
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoinmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
J Med Chem; 2012: 55(7):3274-84. Indice de impacto: 5,248 (JCR2011).

 

Redondo M, Palomo V, Brea J, Pérez DI, Martín-Álvarez R, Pérez C, Paúl-Fernández N, Conde S, Cadavid MI, Loza MI, Mengod G, Martínez A, Gil C, Campillo NE.
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
ACS Chem Neurosci. 2012 Oct 17;3(10):793-803. Indice de impacto: 3.676 (JCR 2011).

 

Lozano MV, Esteban H, Brea J, Loza MI, Torres D, Alonso MJ.
Intracellular delivery of docetaxel using freeze-dried polysaccharide nanocapsules.
J. Microencapsul. 2012 Oct. 22. Indice de impacto: 1,553 (JCR 2011).

 

Areias F, Costa M, Castro M, Brea J, Gregori-Puigjané E, Proença MF, Mestres J, Loza MI.
New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships.
Eur J Med Chem. 2012 Aug;54:303-10. Epub 2012 May 14. Indice de impacto: 3.346 (JCR 2011).

 

Parguiña AF, Alonso J, Rosa I, Vélez P, González-López MJ, Guitián E, Ebble JA, Loza MI, García A.
A detailed proteomic analysis of rhodocytin-activated platelets reveals novel clues on the CLEC-2 signalosome: implications for CLEC-2 signaling regulation.
Blood. 2012 Oct 10. Indice de impacto: 9,898 (JCR 2011).

 

 

inicio

Año 2011


 

Yaziji V, Rodríguez D, Gutiérrez deTerán H, Coelho A, Caamaño O, García-Mera X, Brea J, Loza MI, Cadavid MI, Sotelo E.
Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.
J Med Chem 2011;54(2):457-71. Indice de impacto: 4,802 (JCR 2009).

 

Eastwood P, Esteve C, Gonzalez J, Fonquerna S, Aiguade J, Carranco I, Domenech T, Aparici M, Miralpeix M, Albertí J, Cordoba M, Fernandez R, Pont M, Godessart N, Prats N, Loza MI, Cadavid MI, Nueda A, Vidal B.
Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.
ACS Medicinal Chemistry Letters 2011;2(3):213-218. Indice de impacto: 3.355 (JCR 2010).

 

Costa M, Areias F, Castro M, Brea J, Loza MI, Proença F.
Synthesis of novel chromene scaffolds for adenosine receptors.
Organic and Biomolecular Chemistry 2011, 9(11),4242–4249. Indice de impacto: 3.451 (JCR 2010).

 

Varela MJ, Brea J, Loza MI, Maldonado R, Robledo P.
Sensitization to MDMA locomotor effects and changes in the functionality of 5-HT2A and D2 receptors in mice.
Behavioural Pharmacology. 2011;22(4):362-9. Indice de imparcto: 2,530 (JCR 2010)

 

Barcelo M, Raviña E, Varela MJ, Brea J, Loza MI, Massager CF.
Potential atypical antipsychotics: synthesis, binding affinity and SAR of new heterocyclic bioisosteric butyrophenone analogues as multitarget ligands.
MEDCHEMCOMM 2011; 2(12):1194-1200. Indice de Impacto: 2.800 (JCR 2011).

 

 

inicio

Año 2010


 

Varin T, Gutiérrez-de-Terán H, Castro M, Brea J, Fabis F, Dauphin F, Aqvist J,Lepailleur A, Perez P, Burgueño J, Vela JM, Loza MI, Rodrigo J.
Phe369 (7.38) at human 5-HT7 receptors confers interspecies selectivity to antagonists and partial agonists.
Br J Pharmacol 2010;159(5):1069-81. Indice de impacto: 5,204 (JCR 2009).

 

Selent J, Bauer-Mehren A, López L, Loza MI, Sanz F, Pastor M.
A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints.
Mol Pharmacol 2010: 77(2):149-58. Indice de impacto: 4,531 (JCR 2009).

 

Brea J, Castro-Palomino J, Yeste S, Cubero E, Párraga A, Domínguez E, Loza MI.
Emerging opportunities and concerns for drug discovery at serotonin 5-HT2B receptors.
Curr Top Med Chem 2010;10(5):493-503. Indice de impacto: 4,473 (JCR 2009).

 

Hierrezuelo J, Manuel López-Romero J, Rico R, Brea J, Loza MI, Cai C, Algarra M.
Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors.
Bioorg Med Chem 2010;18(6):2081-8. Indice de impacto: 2,822 (JCR 2009).

 

Areias FM, Brea J, Gregori-Puigjané E, Zaki ME, Carvalho MA, Domínguez E, Gutiérrez-de-Terán H, Proença MF, Loza MI, Mestres J.
In silico directed chemical probing of the adenosine receptor family.
Bioorg Med Chem 2010 May 1;18(9):3043-52. Indice de impacto: 2,822 (JCR 2009).

 

Nieto MI, Balo MC, Brea J, Caamaño O, Fernández F, García-Mera X, López C, Loza MI, Rodríguez-Borges JE, Vidal B.
Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists.
Eur J Med Chem 2010 Jul;45(7):2884-92. Indice de impacto: 3,269 (JCR 2009).

 

Rodríguez-Borges JE, García-Mera X, Balo MC, Brea J, Caamaño O, Fernández F, López C, Loza MI, Nieto MI.
Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists.
Bioorg Med Chem 2010 Mar 1;18(5):2001-9. Indice de impacto: 2,822 (JCR 2009).

 

Lopez L, Selent J, Ortega R, Masaguer CF, Domínguez E, Areias F, Brea J, Loza MI, Sanz F, Pastor M.
Synthesis, 3D-QSAR, and Structural Modeling of Benzolactam Derivatives with Binding Affinity for the D2 and D3 Receptors.
ChemMedChem 2010; 5(8):1300-17. Indice de impacto: 3.232 (JCR 2009).

 

Giovannoni MP, Vergelli C, Cilibrizzi A, Crocetti L, Biancalani C, Graziano A, Piaz VD, Loza MI, Cadavid MI, Díaz JL, Gavaldà A.
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands.
Bioorg Med Chem 2010;18(22):7890-9. Indice de impacto: 2,822 (JCR 2009).

 

Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, Milligan G.
Identification of novel, species selective agonists of the G protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.
Biochem J 2010;432(3):451-9. Indice de impacto: 5,155 (JCR 2009).

 

Alvarez-Lorenzo C, Rey-Rico A, Brea J, Loza MI, Concheiro A, Sosnik A.
Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: branched versus linear derivatives.
Nanomedicine (Lond) 2010;5(9):1371-83. Indice de impacto: 5,982 (JCR 2009).

 

 

inicio

Año 2009


 

Zardaín E, Del Valle MO, Loza MI, García E, Lana A, Markham WA, López ML.
Psychosocial and behavioural determinants of the implementation of Pharmaceutical Care in Spain.
Pharm World Sci 2009;31(2):174-82. Indice de impacto: 0,919 (JCR 2009).

 

Ortega R, Raviña E, Masaguer CF, Areias F, Brea J, Loza MI, López L, Selent J, Pastor M, Sanz F.
Synthesis, Binding Affinity and SAR of New Benzolactam Derivatives as Dopamine D3 Receptor Ligands.
Bioorg Med Chem Lett 2009; 15;19(6):1773-8. Indice de impacto: 2,650 (JCR 2009).

 

Brea J, Castro M, Giraldo J, Lopez-Gimenez JF, Padin JF, Quintian F, Cadavid MI, Vilaro T, Mengod G, Berg KA, Clarke WP, Vilardaga JP, Milligan G, Loza MI.
Evidence for distinct antagonist-revealed functional states of 5-HT2A receptor homodimers.
Mol Pharmacol 2009; 75(6):1380-91. Indice de impacto: 4,531 (JCR 2009)

 

Zhubi A, Veldic M, Puri N.V, Kadriu B, Caruncho H, Loza MI, Sershen H, Lajtha A, Smith R, Guidotti A, Davis J, Costa E.
An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes.
Schizophrenia Resarch 2009;111(1-3):115-22. Indice de impacto: 4,458 (JCR 2009).

 

Fernández F, Caamaño O, Isabel Nieto M, López C, García-Mera X, Stefanachi A, Nicolotti O, Loza MI, Brea J, Esteve C, Segarra V, Vidal B, Carotti A.
1,3-Dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potente adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
Bioorg Med Chem 2009; 15;17(10):3618-29. Indice de impacto: 2,822 (JCR 2009).

 

Gutierrez-de-Teran H, Correia C, Rodriguez D, Carvalho MA, Brea J, Cadavid MI, Loza MI, Proenca MF, Areias F.
Identification of Novel Scaffolds from an Original Chemical Library as Potential Antipsychotics.
QSAR & Combinatorial Science 2009; 28(8):856-860. Indice de impacto: 3,027 (JCR 2009).

 

Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ.
Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.
Int J Pharm 2009; 381(2):122-9. Indice de impacto: 2,962 (JCR 2009).

 

Balo MC, Brea J, Caamaño O, Fernández F, García-Mera X, López C, Loza MI, Nieto MI, Rodríguez-Borges JE.
Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfurylxanthines as adenosine receptor antagonists.
Bioorg Med Chem 2009; 17(18):6755-60. Indice de impacto: 2,822 (JCR 2009).

 

Carro L, Raviña E, Dominguez E, Brea J, Loza MI, F. Masaguer C.
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Bioorganic and Medicinal Chemistry Letters 2009;19(21):6059-6062. Indice de impacto: 2,650 (JCR 2009).

 

Yaziji V, Coelho A, El Maatougui A, Brea J, Loza MI, García-Mera X, Sotelo E.
Divergent solution-phase síntesis of diarylpyrimidine libraries as selective A3 adenosine receptor antagonists.
J. Com. Chem 2009;11(4):519-22. Indice de índice: 3,450 (JCR 2009).

 

Laguna R, Cadavid MI, Castro M, Brea JM, Loza MI.
La experiencia de 10 años de docencia de la asignatura Fuentes de información Farmacológica de Medicamentos impartida con el método de enseñanza basado en la resolución de problemas.
Edusfarma, Revista d’educació superior en Farmàcia 2009. Num 4.

 

 

inicio

Año 2008


 

Stefanachi A, Brea JM, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Vidal B, Carotti A.
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.
Bioorg Med Chem 2008;16(6):2852-69. Indice de impacto: 2,662 (JCR 2007).

 

Martínez A, Gutiérrez-de-Terán H, Brea J, Raviña E, Loza MI, Cadavid MI, Sanz F, Vidal B, Segarra V, Sotelo E.
Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines.
Bioorg Med Chem 2008. 16(4):2103-13. Indice de impacto: 2,624 (JCR 2006).

 

Rico-Gómez R, López-Romero JM, Hierrezuelo J, Brea J, Loza MI, Pérez-González M.
Synthesis of new mannosyl, galactosyl and glucosyl theophylline nucleosides with potential activity as antagonists of adenosine receptors. DEMA-induced cyclization of glycosylideneiminouracils.
Carbohydr Res 2008;343:855-864. Indice de impacto: 1,723 (JCR 2007).

 

Buceta M, Dominguez E, Castro MA, Brea JM, Alvarez D, Barcala J, Valdés L, Alvarez-Calderón P, Domínguez F, Vidal B, Díaz JL, Miralpeix M, Beleta J, Cadavid MI, Loza MI.
A new Chemicals tool (C0036E08) supports the role of adenosine A2B receptors in mediating human mast cell activation.
Biochemical Pharmacology 2008;76(7):912-21. Indice de impacto: 4,006 (JCR 2007).

 

Aranda R, Villalba K, Raviña E, Masaguer CF, Brea J, Areias F, Domínguez E, Selent J, López L, Sanz F, Pastor M, Loza MI.
Synthesis, Binding Affinity, and Molecular Docking Analysis of New Benzofuranone Derivatives as Potential Antipsychotics.
Journal of Medicinal Chemistry 2008;51(19):6085-94. Indice de impacto: 4,895 (JCR 2007).

 

Stefanachi A, Nicolotti O, Leonetti F, Cellamare S, Campagna F, Loza MI, Brea JM, Mazza F, Gavuzzo E, Carotti A.
1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships.
Bioorg Med Chem 2008;16(22):9780-9. Indice de impacto: 2,662 (JCR 2007).

 

 

inicio

Año 2007


 

Domínguez E, Loza MI, Padín F, Gesteira A, Paz E, Páramo M, Brenlla J, Pumar E, Iglesias F, Cibeira A, Castro M, Caruncho H, Carracedo A, Costas J.
Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population.
Schizophrenia Research 2007;90(1-3):123-9. Indice de impacto: 4,260 (JCR 2006).

 

Vidal B, Nueda A, Esteve C, Domenech T, Benito S, Reinoso RF, Pont M, Calbet M, Lopez R, Cadavid MI, Loza MI, Cardenas A, Godessart N, Beleta J, Warrellow G, Ryder H.
Discovery and Characterization of 4'-(2-Furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a Potent, Selective, and Efficacious A2B Adenosine Receptor Antagonist.
Journal of Medicinal Chemistry 2007. 31;50(11):2732-6. Indice de impacto: 5,120 (JCR 2006).

 

Dezi C, Brea J, Alvarado M, Raviña E, Masaguer C, Loza MI, Sanz F, Pastor M.
Multi-structure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor.
Journal of Medicinal Chemistry 2007. 12;50(14):3242-55. Indice de impacto: 5,120 (JCR 2006).

 

Barceló M, Raviña E, Masaguer C, Dominguez E, Areias F, Brea JM, Loza MI.
Synthesis and Binding Affinity of New Pyrazole and Isoxazole Derivatives as Potential Atypical Antipsychotics.
Bioorganic and Medicinal Chemistry Letters 2007. 17(17):4873-7. Indice de impacto: 2,540 (JCR 2006).

 

 

inicio

Año 2006


 

Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz E, Segarra V, Sotelo E, Stefanachi A, Vidal B.
Design, synthesis and structure-activity relationships at human A2B adenosine receptor of 1-,3-,8-and 9-substituted-9-deazaxanthines.
Journal of Medicinal Chemistry 2006;49(1):282-99. Indice de impacto: 5,120 (JCR 2006).

 

Esteve C, Nueda A, Diaz JL, Beleta J, Cardenas A, Lozoya E, Cadavid MI, Loza MI, Ryder H, Vidal B.
New pyrrolopyrimidin-6-yl benzenesulfonamides: Potent A2B adenosine receptor antagonists.
Bioorganic & Medicinal Chemistry Letters 2006;16(14):3642-5. Indice de impacto: 2,540 (JCR 2006).

 

Brea J, Castro M, Loza MI, Masaguer CF, Ravina E, Dezi C, Pastor M, Sanz F, Cabrero-Castel A, Galan-Rodriguez B, Fernandez-Espejo E, Maldonado R, Robledo P.
QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine.
Neuropharmacology 2006;51(2):251-62. Indice de impacto: 3,860 (JCR 2006).

 

Padín JF, Rodríguez MA, Domínguez E, Dopeso-Reyes IG; Buceta M; Cano E; Sotelo E, Brea J, Caruncho HJ; Cadavid MI, Castro MA; Loza MI.
Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells.
Neuropharmacology 2006;51(4):923-32. Indice de impacto: 3,860 (JCR 2006).

 

Caruncho HJ, Loza MI.
Tendiendo puentes entre la psiquiatria y las neurociencias.
Rev Gal Psiq Neuroc 2006; 5:7-8.

 

 

inicio

Año 2005


 

Alvarado M, Coelho A, Masaguer CF, Raviña E, Brea J, Padín JF, Loza MI.
Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics.
Bioorganic & Medicinal Chemistry Letters 2005;15(12):3063-6. Indice de impacto: 4,480 (JCR 2005).

 

inicio

Año 2004


 

Caro Y, Torrado M, Masaguer CF, Raviña E, Padín F, Brea J, Loza MI.
Chemoenzymatic syntesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potencial atypical antipsychotics.
Bioorganic & Medicinal Chemistry Letters 2004;14(3):585-589. Indice de impacto: 2,330 (JCR 2004).

 

Cordero L, Cadavid MI, Fernández-Llimós F, Díaz C, Sanz F, Loza MI.
Continuing education and community pharmacists of Galicia: An opinión study.
PWS Pharmacy World & Science 2004;26(3):173-177. Indice de impacto: 0,850 (JCR 2004).

 

Domínguez E, Padín F, Cadavid MI, Loza MI.
Integración del Estudio Farmacogenético y Farmacogenómico de la Esquizofrenia (EFFE) en la Red INBIOMED.
Informática y Salud 2004; 46:38-40.

 

Bosch MP, Campos F, Niubó I, Rosell G, Díaz JL, Brea J, Loza MI, Guerrero A.
Síntesis and biological activity of new potential agonists for the human adenosine A2A receptor.
Journal of Medicinal Chemistry 2004;47(16):4041-53. Indice de impacto: 5,080 (JCR 2004).

 

Carotti A, Stefanachi A, Raviña E, Sotelo E, Loza MI, Cadavid MI, Centeno N, Nicoletti O.
8-Sbustituted-9-deazaxanthines as adenosine receptor ligando: design, síntesis and structure-affinity relationships at A2B.
European Journal of Medicinal Chemistry 2004;39(10):879-87. Indice de impacto: 1,670 (JCR 2004).

 

Caruncho HJ, Dopeso-Reyes I, Loza MI, Rodríguez MA.
GABA, Reelin, and the neurodevelopmental hypothesis of schizophrenia.
Critical ReviewsTM in Neurobiology 2004;16(1-2):25-32. Review.

 

 

inicio

Año 2003


 

González-Gómez JC, Santana L, Uriarte E, Brea J, Villazón, Loza MI, De Luca M, Rivas ME, Montenegro GY, Fontenla JA.
New arylpiperazine derivatives with higt affinity for Alfa1A, D2 and 5-HT2A receptors.
Bioorganic & Medicinal Chemistry Letters 2003; 13(2):175-178. Indice de impacto: 1,680 (JCR 2003).

 

Brea J, Christian F, Villazón M, Cadavid MI, Raviña E, Fontaine F, Dezi C, Pastor M, Sanz F, Loza MI.
Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviorus.
European Journal of Medicinal Chemistry 2003;38(4):433-440. Indice de impacto: 1,680 (JCR 2003).

 

Orallo F, Gª-Ferreiro T, Enguix MJ, Tristan H, Fdez-Masaguer C, Raviña E, Cadavid MI, Loza MI.
In vivo and in vitro pharmacological studies of a new hypotensive compound (QF0301B) in rat: comparison with prazosin, a known alfa1-adrenoceptor antagonist.
Vascular Pharmacology 2003;40(2):97-108. Indice de impacto: 1,050 (JCR 2003).

 

Enguix MJ, Sánchez L, Villazón M, Brea J, Tristán H, Caruncho HJ, Cadavid MI, Loza MI.
Differential regulation of rat peripheral 5-HT2A and 5-HT2B receptors systems: influence of drug treatment.
Naunyn-Schmiedeberg’s archives of pharmacology 2003;368(2):79-90. Indice de impacto: 2,100 (JCR 2003).

 

Villazón, M, Enguix MJ, Tristán H, Honrubia MA, Brea J, Maayani S, Cadavid MI, Loza MI.
Different pharmacological properties of two equipotent antagonists (clozapine and rauwolscine) for 5-HT2B receptors in rat stomach fundus.
Biochemical Pharmacology 2003;66(6):927-937. Indice de impacto: 2,990 (JCR 2003).

 

 

inicio

Año 2002


 

Brea J, Rodrigo J, Carrieri A, Sanz F, Cadavid MI, Enguix M, Villazón M, Mengod G, Caro Y, Massaguer CF, Raviña E, Centeno NB, Carotti A, Loza MI.
New serotonina 5-HT2A, 5-HT2B and 5-HT2C receptor antagonists: synthesis, pharmacology, 3D QSAR and molecular modelling of (aminoakyl) benzo and heterocycloalkanones.
Journal of Medicinal Chemistry 2002;45(1):54-71. Indice de impacto: 4.570 (JCR 2002).

 

Honrubia M, Rodrigo J, Cadavid MI, Calleja JM, Sanz F, Loza MI.
Influence of pH on the binding of diphenylmethylenepiperidines by 5-HT2B receptors in rat stomach fundus.
Chemicall & Pharmaceutical Bulletin 2002;50(3):395-8. Indice de impacto: 1,130 (JCR 2002).

 

Villazón M, Padín JF, Cadavid MI, Enguix M, Tristán H, Orallo F, Loza MI.
Functional Characterization of Serotonin Receptors in Rat Isolated Aorta.
Biological and Pharmaceutical Bulletin 2002; 25(5):584-590. Indice de impacto: 1040 (JCR 2002).

 

Pastor M, Benedetti P, Carotti A, Carrieri A, Díaz C, Herráiz C, Hölje H-D, Loza MI, Opresa R, Padín F, Pubill F, Sanz F, Stoll F.
The LINK3D consortium. Distant collaboration in drug discovery: The LINK3D project.
Journal of Computer Aided Molecular Design 2002;16(11):809-818. Indice de impacto: 2,930 (JCR 2002).

 

 

inicio

Año 2001


 

Cordero L, Fernández-Llimós F, Cadavid MI, Giorgio F, Loza MI y los miembros del Panel Multidisciplinar TESEMED.
Protocolos para trastornos menores del Proyecto TESEMED: Gripe y Resfriado.
Pharmaceutical Care España 2001;3(1):5-21.

 

Loza MI, Cordero L, Fernández-Llimós F, Cadavid MI, Calleja JM, Giorgio F, Alonso A, Mircheva J.
Protocolos para trastornos menores del Proyecto TESEMED: Tos.
Pharmaceutical Care España 2001;3(2):77-92.

 

Cordero L, Fernández-Llimós F, Cadavid MI, Giorgio F, Loza MI y los miembros del Panel Multidisciplinar TESEMED.
Protocolos para trastornos menores del Proyecto TESEMED: Estreñimiento.
Pharmaceutical Care España 2001;3(3):151-236.

 

Cordero L, Fernández-Llimós F, Cadavid MI, Giorgio F, Loza MI y los miembros del Panel Multidisciplinar TESEMED.
Protocolos para trastornos menores del Proyecto TESEMED: Hemorroides.
Pharmaceutical Care España 2001;3(5):324-336.

 

López-Jiménez JF, Villazón M, Brea J, Loza MI, Palacios JM, Mengod G, Vilaró MT.
Múltiple conformations of native and recombinant human 5-HT2A receptors are labeled agonists and discriminated by antagonists.
Molecular Pharmacology 2001;60(4):690-699. Indice de impacto: 5,300 (JCR 2001).

 

 

inicio

Año 2000


 

Ravina E, Casariego I, Masaguer CF, Fontenla JA, Montenegro GY, Rivas ME, Loza MI, Enguix MJ, Villazon M, Cadavid MI, Demontis GC.
Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Journal of Medicinal Chemistry 2000; 30;43(24):4678-93. Indice de impacto: 4,130 (JCR 2000).

 

Masaguer CF, Raviña E, Fontenla JA, Brea JM, Tristán H, Loza MI.
Butyrophenone analogues in the carbazole series as potential atypical antipsychotic. Synthesis and determination of affinities at D; 5-HT2A and 5-HT2c receptors.
European Journal of Medicinal Chemistry 2000;35:83-95. Indice de impacto: 1,310 (JCR 2000).

 

Fernández-Llimós F, Loza MI.
Product monographs supplied by drug manufacturers to community pharmacists in Spain.
Annals of Pharmacotherapy 2000;34,407. Indice de impacto: 1,870 (JCR 2000).

 

Loza MI, Cordero L, Fernández-Llimós F, García P, Cadavid MI, Sanz F, Calleja JM.
Drug information sources used by community pharmacists in Galicia.
Pharmaceutical Care España 2000;2(2):108-122.

 

Orallo F, Tristan H, García-Ferreiro T, Francisco-Baña S, Masaguer CF, Raviña E, Calleja JM, Cadavid MI, Loza MI.
Study of the in Vivo and in Vitro Cardiovascular Effects of Four New Analogues of Ketanserin: Implication of 5-HT2A and 1 Adrenergic Antagonism in Their Hypotensive Effect.
Biological & Pharmaceutical Bulletin 2000;23(5):558-565. Indice de impacto: 1,180 (JCR 2000).

 

Sanz F, Silveira C, Díaz C, Alonso A, Loza MI, Cordero L, Fernández-Llimós F, Cadavid MI, Tiddens L, Giorgio F, Cranz H, Henderson K, Mircheva J, Fernández JL.
Information technology in community pharmacies for supporting responsible self-medication.
American Journal of Health-Systems Pharmacy 2000;57: 1601-1603. Indice de impacto: 1,150 (JCR 2000).

 

Loza MI, Cordero L, Fernández-Llimós F, Cadavid MI, Calleja JM, Sanz F, Silveira C, Díaz C, Alonso A, Giorgio F, Tiddens L, Cranz H, Mircheva J.
El Proyecto TESEMED; Aprender en las farmacias comunitarias utilizando la telemática.
Pharmaceutical Care España 2000;2(6): 440-443.

 

Orallo F., Rosa E, Gª-Ferreiro T, Campos-Toimil M, Cadavid M.I, Loza MI.
Cardiovascular effects of ketanserin on normotensive rats in vivo and in vitro.
General Pharmacology 2000;35:95-105. Indice de impacto: 1,140 (JCR 2000).

 

inicio

Año 1999


 

Raviña E, Negreira J, Cid J, Masaguer CF, Rosa E, Rivas E, Fontenla JA, Loza MI, Tristán H, Cadavid MI, Sanz F, Lozolla E, Carrieri A.
Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2A, 5-HT2C) affinities. Synthesis, pharmacology, 3D-QSAR and molecular modelling of aminoalkyl benzo and thienocycloalkanones as putative atypical antipsychotic.
Journal of Medicinal Chemistry 1999;42(15): 2774-97. Indice de impacto: 4,080 (JCR 1999).

 

Sanz F, Silveira C, Alonso A, Díaz C, Loza MI, Cordero L, Fernández-Llimós F, Tiddens L, Giorgio F, Cranz H, Mircheva J.
Telematics applications to support the role of the community pharmacists as self-medication advisors.
TESEMED Consortium. Studies in Health and Technology Informatics 1999; 68: 764-767.

 

Cordero L, Fernández-Llimós F, Corral P, Cadavid M, Sanz F, Loza MI.
Fuentes de Información sobre Medicamentos Utilizadas por los Farmacéuticos Comunitarios de Galicia. I Congreso Nacional de Atención Farmacéutica.
COF Guipúzcoa (Eds) 1999:243-243.

 

inicio

Año 1998


 

Lozoya E, Berges M, Rodriguez J, Sanz F, Loza MI, Moldes VM, Masaguer CF.
Comparison of electrostatic similarity approaches applied to a series of ketanserin analogues with 5-HT2A antagonistic activity.
Quantitative Structure-Activity Relationships (QSAR) 1998; 17: 199-204. Indice de impacto: 1,970 (JCR 1998).

 

Masaguer CF, Formoso E, Raviña E, Tristán H, Loza MI, Rivas E, Fontenla JA.
Butirophenone analogues in the carbazole series: synthesis and determination of affinities at D2 and 5-HT2A receptors.
Bioorganic & Medicinal Chemistry Letters 1998; 8: 3571-3576. Indice de impacto: 1,500 (JCR 1998).

 

Vazquez JA, Iñesta A, Loza MI, Torres C.
Fármacos de utilidad terapéutica baja (UTB) más prescritos en el Sistema Nacional de Salud.
La Revista O.F.I.L. (Organización Farmacéutica Ibero-Latinoamericana).1998; 3(8):22-34.

 

inicio

Año 1997


 

Honrubia MA, Rodriguez J, Dominguez R, Lozoya E, Manaut F, Seijas JA, Villaverde MC, Calleja JM, Cadavid MI, Maayani S, Sanz F, Loza MI.
Synthesis, activity at 5-HT2A, 5-HT2B, and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues.
Chemical and Pharmaceutical Bulletin 1997; 45: 842-848. Indice de impacto: 1,140 (JCR 1998).

 

Masaguer CF, Raviña E, Loza MI, Fontenla JA.
New cyclic butyrophenone derivatives in the indole series as potential atypical antipsichotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinities for D1, D2 and 5-HT2A receptors.
Bioorganic and Medicinal Chemistry Letters 1997; 7: 913-918. Indice de impacto: 1,500 (JCR 1998).

 

Sanz F, Sosa-Iudicissa M, Castón O, Loza MI.
Contribuciones de la telemática al diseño, evaluación y uso de medicamentos.
Telemedicine 1997; 30-37.

 

inicio

Año 1996


 

Raviña E, Fueyo J, Masaguer CF, Negreira J, Cid J, Loza MI, Honrubia MA, Tristan H, Gª-Ferreiro T, Fontenla JA, Rosa E, Calleja JM, Ceballos ML.
Synthesis and affinities for D2 and 5-HT2A receptors of N1- (Benzoylpropyl)-N2- (1-oxocycloalkyl-2-ethyl) piperazines as cyclic butyrophenone derivatives.
Chemical and Pharmaceutical Bulletin 1996; 44: 534-541. Indice de impacto: 1,140 (JCR 1998).

 

Sanz F, Loza MI, Ahlgrimm ED, Baetens P, Sosa-Iudicissa M.
Over the Counter Drugs: Telematics will be useful in providing information.
British Medical Journal 1996; 313: 116. Indice de impacto: 5,330 (JCR 1998).

 

inicio

Año 1995


 

Raviña E, Masaguer CF, Cid J, Casariego I, Fontenla JA, Gª-Ferreiro T, Cadavid MI, Loza MI, de Ceballos, ML.
Butyrophenone analogues: synthesis of 2-methyl-3-ethyl- 5-aminoethyl-4, 5, 6, 7-tetrahydroindol-4-ones, and their affinities for D1, D2 and 5-HT2A receptors.
Bioorganic & Medicinal Chemistry Letters 1995; 5: 579-584. Indice de impacto: 1,500 (JCR 1998)

 

inicio

Año 1994


 

Campos M, Orallo F, Gil-Longo J, Verde I, Loza MI, Fernández-Alzueta, A.
Pharmacological study of several effects of hydralazine in the bisected rat vas deferens.
European Journal of Pharmacology 1994; 251: 83-90. Índice de impacto: 1,990 (JCR 1998).

 

Fontenla JA, Osuna J, Rosa E, Castro E, Gª- Ferreiro T, Loza MI, Calleja JM, Sanz F, Rodríguez J, Raviña E, Fueyo J, Fdez-Masaguer C, Vidal A, Ceballos ML.
Synthesis and atypical antipsychotic profile of some 2-aminoethyben-zociclanones as analogues of butyrophenone.
Journal of Medicinal Chemistry 1994; 37: 2564-2573. Índice de impacto: 3,740 (JCR 1998).

 

Castro ME, Rosa E, A-Osuna J, G-Ferreiro T, Loza MI, Cadavid MI, Fontenla JA, Masaguer C, Cid J, Raviña E, García-Mera G, Rodriguez J, de Ceballos ML.
Piridazine derivatives XII. Synthesis and antipsychotic-antidepressant activity of some butyrophenone derivatives of 6-phenylpyridazine.
European Journal of Medicinal Chemistry 1994; 29: 831-839. Índice de impacto: 1,120 (JCR 1998).

 

inicio

Año 1993


 

Loza MI, G-Ferreiro T, Sanz F, Lozoya E, Rodriguez J, Manaut I, Verde I, Castro E, Fontenla JA, Cadavid MI, Honrubia M, Fueyo J, Raviña E.
Antiserotoninergic activity of 2-aminoethylbenzocyclanones in rat aorta: structure-activity relationships.
Journal of Pharmaceutical Sciences 1993; 82(5): 513-517. Índice de impacto: 1,760 (JCR 1998).

 

Loza MI, Orallo F, Verde I, Cadavid MI, Gil J, Calleja JM.
A study of glaucine-induced relaxation of rat aorta.
Planta Medica 1993; 59: 229-231. Índice de impacto: 1,320 (JCR 1998).

 

Loza MI, Baamonde A, Hidalgo A, Andrés-Trelles F.
Potenciación por dipirona magnésica y dipirona sódica de la hipotermia producida por clorpromazina en rata anestesiada.
Anales de la Real Academia de Farmacia 1993; 59: 181-190.

 

Loza MI, Sanz F, Cadavid MI, Honrubia M, Orallo F, Fontenla JA, Calleja JM, Dot T, Manaut F, Cid MM, Domínguez R, Seijas JA, Villaverde MC.
Cyproheptadine analogues. Synthesis, antiserotoninergic activity and structure-activity relationships.
Journal of Pharmaceutical Sciences 1993; 82(11): 1090-1093. Índice de impacto: 1,760 (JCR 1998).

 

Orallo F, Alzueta AF, Loza MI, Vivas N, Badia A, Campos M, Honrubia MA, Cadavid MI.
Study of the mechanism of the relaxant action of (+)-glaucine in rat vas deferens.
British Journal of Pharmacology 1993; 110:943-948. Índice de impacto: 3,700 (JCR 1998).

 

inicio

Año 1992


 

Orallo F, Verde I, Loza MI, Alzueta AF, Campos M, Freire-Garabal M.
Effects of platelet activating factor (PAF) on contractions and 45Ca influx induced by noradrenaline and potassium in rubbed and intact rat aorta. Comparison with its hypottensive effect in anaesthetized normotensive rat.
Journal of Pharmacy and Pharmacology 1992; 44: 344-348. Índice de impacto: 0,790 (JCR 1998).

 

Orallo F, Fontenla JA, Loza MI, Campos M, Calleja JM.
Effect of urethane on hydralazine-induced tachycardia in rats.
General Pharmacology 1992; 23: 1143-1147. Índice de impacto: 1,040 (JCR 1998).

 

inicio

Año 1991


 

Loza MI, Verde I, Castro ME, Orallo F, Fontenla JA, Calleja JM, Raviña E, Cortizo L, De Ceballos ML.
5-HT2 antagonist activity of 3-aminomethyltetralones.
Bioorganic and Medicinal Chemistry Letters 1991; 12, 717- 720. Índice de impacto: 1,500 (JCR 1998).

 

Freire-Garabal M, Couceiro J, Balboa JL, Nuñez MJ, Fernandez-Rial JC, Cimadevilla B, Gutierrez C, Loza MI, Belmonte A.
Effects of diazepam on the resistance, on the development of immunity and on the passive transfer of immunity to Listeria monocitogenes in mice submitted to surgical stress.
Acta Therapeutica 1991; 17: 355-362. Índice de impacto: 0,430 (JCR 1998).

 

inicio

Año 1988


 

Loza MI, Hidalgo A, Andrés-Trelles F.
Efecto espasmolítico in vitro de la dipirona frente a BaCl2. Comparación de las sales sódica y magnésica.
Revista Española de Farmacología Clínica y Experimental 1988; 4: 389-395.

 

Llavona AM, Loza MI.
Estudio de automedicación desde una oficina de farmacia.
El Farmacéutico 1988; 54: 61-68. (En 1988 no había revistas indexadas para este ámbito profesional).

 

inicio